# US 11,111,246 B2 · Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,246 B2
- Document ID: US11111246B2
- Status: Granted
- Kind: B2
- Application number: 16/705,814
- Filed: 2019-12-06
- Published: 2020-07-16
- Granted: 2021-09-07
- Earliest claimed: 2008-07-21
- Assignees: Purdue Pharma L.P.
- Applicants: Purdue Pharma L.P.
- Inventors: Jiangchao Yao; John W. F. Whitehead; Naoki Tsuno; Kouki Fuchino
- Web page: https://patentgrep.com/patent/US11111246B2

## CPC

- C07D 471/08: Bridged systems
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/12: Antihypertensives
- A61P 11/04: for throat disorders
- A61P 11/14: Antitussive agents
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 451/14: containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to Substituted-Quinoxaline-Type Bridged-Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

## Claims

### Claim 1

A pharmaceutically acceptable salt of a compound selected from the group consisting of
wherein the pharmaceutically acceptable salt is selected from the group consisting of a p-toluenesulfonic acid salt, a sulfuric acid salt, a phosphoric acid salt, and a hydrochloric acid salt.

### Claim 2 (depends on 1)

The pharmaceutically acceptable salt of claim 1, wherein the pharmaceutically acceptable salt is a p-toluenesulfonic acid salt.

### Claim 3 (depends on 2)

The pharmaceutically acceptable salt of claim 2, wherein the compound is

### Claim 4 (depends on 2)

The pharmaceutically acceptable salt of claim 2, wherein the compound is

### Claim 5 (depends on 2)

The pharmaceutically acceptable salt of claim 2, wherein the compound is